As mentioned last couple of weeks, there is more effort given to MicroRNA in the diagnosis and treatment of cancer. We’re at it again, with what I think is a great announcement; Ohio State is partnering with Micro Bio, Inc. This partnership licenses nearly 100 issued and pending microRNA patents.
The Ohio State University today announced the signing of an exclusive world-wide agreement with Microlin Bio Inc., licensing a large portfolio of Ohio State’s groundbreaking cancer discoveries. The portfolio includes nearly 100 issued and pending microRNA patents that could lead to entirely new, more effective and more targeted ways to diagnose and treat prostate, ovarian, colon and lung cancers. Additionally, Microlin Bio Inc. has licensed a novel nucleic acid delivery technology to deliver these transformational therapies to cancer cells.
I’m actually glad to see the commercialization of OSU’s research. This arrangement gets the patent information into the hands of an entity that can, hopefully, take this work and “bring it to market” where the OSU results can be use for diagnosis and treatment. Similarly, Roswell Park Cancer Institute (RPCI) in Buffalo has licensed/spun off various research into commercial endeavors to get their research to market. Ohio State will also have an equity position in Microlin Bio Inc.
“Our goal is to support the researchers at Ohio State in the commercialization process,” says Erin Bender, associate director of Ohio State’s Technology Commercialization Office, whose team worked on the license deal. “We believe that the licensing of these technologies will transform the care of cancer patients in Ohio and throughout the world.”
I think it is interesting that OSU will take an equity position in this venture. I’m speculating, since I don’t know the deal details, but it seems that OSU, in addition to receiving financial licensing benefits, will have a significant say in the development of their work. I like this business model. It’ll be good for OSU and it will be good for the medical community.